Clinical Trial Search

Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001

Primary: Five-year Disease-free Survival (DFS) Rate — 85.3; 86.3 percentage of participants — p=<0.001

Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Toxicity — 2; 0 Events

Primary: Disease-specific Survival (DSS) (10-year Rates Reported) — 95; 96 percentage of participants — p=0.45

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Overall Survival — 5.8; 5.1 years — p=0.15

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Number of Participants Free From Progression at 3 Years — 54 participants

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001

Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Overall Survival (5-year Rate Reported) — 84.9; 87.2 percentage of participants — p=0.81

Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants

Primary: Overall Survival — 88.7; 93.3 percentage of participants — p=0.0398

Primary: Overall Survival Rate (10-year) — 61.9; 56.8 percentage of patients — p=0.0309

Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…

Primary: Progression-free Survival — 13 months

Primary: Time to Objective Disease Progression — 11.7; 10.0 Weeks — p=0.052

Primary: Overall Survival (OS) Time — 29.73; 28.65 months — p=0.3667

Primary: Overall Survival — 87; 86 percentage of probability of survival — p=0.70

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Percentage of Participants With Biochemical Failure (Primary Endpoint of Revised Protocol) — 17.3; 12.8 percentage of participants — p=0.55

Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants